The antibody-drug conjugate stretched out time to progression in a Phase III trial of pretreated patients with advanced hormone receptor-positive, HER2-negative breast cancers.
Advanced breast cancer patients could be given a year or more of extra healthy life by a Trojan horse treatment that destroys tumour cells from the inside out.